Treatment with emibetuzumab induces reductions in phosphorylated and total c-MET levels, leading to the inhibition of cell proliferation and tumor growth in gastric cancer cell lines (MKN-45 and SNU-5) as well as in NSCLC cell lines (EBC-1 and H1993). The gene discussed is MET; the disease is gastric cancer.